« Return to News | CROs/Service Providers

Chiltern establishes legal entity in Israel

Thursday, July 7, 2011 10:11 AM

Global CRO Chiltern International has established a new legal entity in Israel.

“Chiltern has experienced a healthy number of requests from our clients in this region, and forming a legal entity is a natural progression to our work there,” said Armand Czaplinski, Chiltern’s executive director of global country management, who will be leading the effort in Israel.

“Israel is an attractive location to conduct clinical trials as it has many key opinion leaders (KOL) in clinical research and outstanding quality of research,” he said. “Israel has some of the most skilled and educated work forces with the highest number of doctors, scientists and engineers per capita than any other country. Another key advantage is that the majority of Israel’s population belongs to the same health maintenance organization and this facilitates a quick start for clinical trials and reduces the overall project timelines.”

Glenn Kerkhof, Chiltern CEO, said, “We are delighted to add Israel to our established global footprint to better serve our clients. It is essential for Chiltern to have operations in Israel to tap into the renowned clinical research expertise, experienced investigators and key opinion leaders available in this country.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.